Search Results - "Hankosky, Emily R"

Age- and sex-dependent effects of methamphetamine on cognitive flexibility and 5-HT2C receptor localization in the orbitofrontal cortex of Sprague-Dawley rats by Hankosky, Emily R., Westbrook, Sara R., Haake, Rachel M., Willing, Jari, Raetzman, Lori T., Juraska, Janice M., Gulley, Joshua M.

“…•Drug-induced neuroadaptations and cognitive impairment depend on age and sex.•Methamphetamine self-administration impairs reversal learning in adolescent…”
Get full text

X-search: an open access interface for cross-cohort exploration of the National Sleep Research Resource by Cui, Licong, Zeng, Ningzhou, Kim, Matthew, Mueller, Remo, Hankosky, Emily R, Redline, Susan, Zhang, Guo-Qiang

“…The National Sleep Research Resource (NSRR) is a large-scale, openly shared, data repository of de-identified, highly curated clinical sleep data from multiple…”
Get full text

Integrating data science into the translational science research spectrum: A substance use disorder case study by Slade, Emily, Dwoskin, Linda P, Zhang, Guo-Qiang, Talbert, Jeffery C, Chen, Jin, Freeman, Patricia R, Kantak, Kathleen M, Hankosky, Emily R, Fouladvand, Sajjad, Meadows, Amy L, Bush, Heather M

“…The availability of large healthcare datasets offers the opportunity for researchers to navigate the traditional clinical and translational science research…”
Get full text

The changing landscape of naloxone availability in the United States, 2011 – 2017 by Freeman, Patricia R., Hankosky, Emily R., Lofwall, Michelle R., Talbert, Jeffery C.

“…•Opioid overdose deaths have been on the rise in the US since 1999.•States have implemented laws to increase access to the opioid antagonist, naloxone.•Number…”
Get full text

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis by Hankosky, Emily R., Wang, Hui, Neff, Lisa M., Kan, Hong, Wang, Fangyu, Ahmad, Nadia N., Griffin, Ryan, Stefanski, Adam, Garvey, W. Timothy

“…Aim To assess the effect of tirzepatide on long‐term risk of atherosclerotic cardiovascular disease (ASCVD) among people with obesity or overweight without…”
Get full text

70-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—Post Hoc Analysis of the SURMOUNT-1 Trial by HANKOSKY, EMILY R., WANG, HUI, NEFF, LISA M., KAN, HONGJUN, WANG, FANGYU, AHMAD, NADIA, STEFANSKI, ADAM, TIMOTHY GARVEY, W.

“…Background: The effect of tirzepatide (TZP) on the risk of developing type 2 diabetes (T2D) in people with obesity or overweight is unknown. We aimed to assess…”
Get full text

71-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—SURMOUNT-1 Post Hoc Analysis by Prediabetes Status by HANKOSKY, EMILY R., WANG, HUI, NEFF, LISA M., KAN, HONGJUN, WANG, FANGYU, AHMAD, NADIA, STEFANSKI, ADAM, TIMOTHY GARVEY, W.

“…Background: This study assessed the effect of tirzepatide (TZP) on the 10-year risk of developing type 2 diabetes (T2D) in people with overweight or obesity…”
Get full text

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial by Hankosky, Emily R., Wang, Hui, Neff, Lisa M., Kan, Hong, Wang, Fangyu, Ahmad, Nadia N., Stefanski, Adam, Garvey, W. Timothy

“…Abstract Aim We assessed the impact of tirzepatide on 10‐year predicted risk of developing type 2 diabetes (T2D) among participants in the SURMOUNT‐1 trial…”
Get full text

658-P: Gaps Remain for Achieving Guideline-Recommended and Individualized HbA1c Targets for People with Type 1 and Type 2 Diabetes Using Mealtime Insulin or Basal-Only Insulin by HANKOSKY, EMILY R., SCHAPIRO, DAVID, GUNN, KARLI B., LUBELCZYK, ELIZABETH, MITROI, JESSICA, NELSON, DAVID R.

“…Background: HbA1c is a primary measure of glycemic control and managing HbA1c may help reduce the risk of complications. This study aimed to describe trends in…”
Get full text

557-P: Patient and Caregiver Experiences during Severe Hypoglycemia: A Qualitative Assessment by STUCKEY, HEATHER L., DESAI, URVI, KING, SARAH B., POPADIC, LYUBA, LEVINSON, WILL, KIRSON, NOAM, HANKOSKY, EMILY R., MITCHELL, BETH

“…Among people with diabetes (PWD) using insulin, severe hypoglycemia (SH) can be a life threatening complication, if untreated. The personal experiences of SH…”
Get full text

4-LB: Adaptation and Performance of a Validated Hypoglycemia Risk Stratification Tool in a U.S Claims Database by HANKOSKY, EMILY R., VALLARINO, CARLOS R., FALCON, BEVERLY, WONG-JACOBOSN, SIEW HOONG, BENTZ, BOBBI B., MITCHELL, BETH

“…Aims: Karter et al. validated a hypoglycemia risk stratification tool using electronic medical records that classifies 12-month risk of hypoglycemia-related…”
Get full text

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison by Roux, Carel W., Hankosky, Emily R., Wang, Duzhe, Malik, Raleigh, Yu, Maria, Hickey, Ana, Kan, Hong, Bunck, Mathijs C., Stefanski, Adam, Garcia‐Perez, Luis‐Emilio, Wharton, Sean

“…Aim To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Materials and Methods Using SURMOUNT‐1…”
Get full text

Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning by Hankosky, Emily R., Katz, Michelle L., Fan, Ludi, Liu, Dongju, Chinthammit, Chanadda, Brnabic, Alan J. M., Eby, Elizabeth L.

“…Insulin pump use is increasing among people with type 2 diabetes (T2D), albeit at a slower rate compared to people with type 1 diabetes (T1D). Factors…”
Get full text

Association between state Medicaid expansion status and naloxone prescription dispensing by Sohn, Minji, Talbert, Jeffery C., Delcher, Chris, Hankosky, Emily R., Lofwall, Michelle R., Freeman, Patricia R.

“…Objective To test whether Medicaid expansion is associated with (a) a greater number of naloxone prescriptions dispensed and (b) a higher proportion of…”
Get full text

The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: “What am I going to do?” by Stuckey, Heather L., Desai, Urvi, King, Sarah B., Popadic, Lyuba, Levinson, William, Kirson, Noam Y., Hankosky, Emily R., Mitchell, Beth

“…Aims Among people with diabetes using insulin, severe hypoglycaemia (SH) can be a life‐threatening complication, if untreated. The personal experiences during…”
Get full text

75-LB: Use of Continuous Glucose Monitoring (CGM) and Its Association with Economic Outcomes in the Real-World Setting by PEREZ-NIEVES, MAGALY, HANKOSKY, EMILY R., FAN, LUDI, GELSEY, FELICIA, EBY, ELIZABETH L., SIMS, TRACY J., UMEH, EMEKA, JUNEJA, RATTAN

“…Background: CGM is increasingly used as tool in the management of diabetes, supporting improvements in glycemic control and quality of life. Objectives: The…”
Get full text

Age and Sex Differences in Behavioral Flexibility, Sensitivity to Reward Value, and Risky Decision-Making by Westbrook, Sara R., Hankosky, Emily R., Dwyer, Megan R., Gulley, Joshua M.

“…Compared with adults, adolescent behavior is often characterized by reduced behavioral flexibility, increased sensitivity to reward, and increased likelihood…”
Get full text

Reduced sensitivity to reinforcement in adolescent compared to adult Sprague-Dawley rats of both sexes by Hankosky, Emily R., Westbrook, Sara R., Haake, Rachel M., Marinelli, Michela, Gulley, Joshua M.

“…Rationale Adolescence is a period of considerable development of brain and behavior and is the time during which most drug use is initiated. Objective…”
Get full text

Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting by Brett McQueen, Robert, Perez-Nieves, Magaly, Todd Alonso, G., Fan, Ludi, Hankosky, Emily R., Shah, Viral N., Yan, Yuer, Ellis, Samuel L., Juneja, Rattan

“…•Consensus statements have set targets for CGM metrics, supported by RCT data.•We analyzed real-world CGM and clinical data to assess how these targets…”
Get full text

73-LB: Continuous Glucose Monitoring Utilization and Associated Metrics in People with Diabetes on Insulin Therapy in the U.S by PEREZ-NIEVES, MAGALY, HANKOSKY, EMILY R., FAN, LUDI, GELSEY, FELICIA, EBY, ELIZABETH L., SIMS, TRACY J., UMEH, EMEKA, BETTS, MICHAEL, LAVALLEE, CHRIS, JUNEJA, RATTAN

“…Background: Continuous glucose monitoring (CGM) systems generate real-time information on blood glucose trends in PwD, providing regular feedback that may help…”
Get full text